You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Mediastinal B-Cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

    Active, not recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • DISEASE
    • (no location specified)
    May 4, 2023

    Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma Trial in United States (ADI-001, Fludarabine,

    Recruiting
    • Lymphoma, Follicular
    • +5 more
    • ADI-001
    • +2 more
    • Stanford, California
    • +6 more
    Oct 19, 2022

    Cardiovascular Events Among Adults Relapsed or Refractory

    Recruiting
    • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
    • +9 more
    • Electronic Health Record Review
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

    Available
    • Large B-cell Lymphoma
    • +4 more
    • Epcoritamab
    • (no location specified)
    Feb 16, 2023

    Allogeneic Gamma Delta (?d) CAR T Cells

    Enrolling by invitation
    • Lymphoma, Follicular
    • +5 more
    • ADI-001
    • Stanford, California
    • +4 more
    Jun 7, 2022

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

    Active, not recruiting
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, DLBCL Transformed From Follicular Lymphoma Trial run by the

    Completed
    Has Results
    • Primary Mediastinal B-cell Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Dec 29, 2021

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 9, 2022

    Lymphoma, B-Cell Trial in Japan (Pembrolizumab)

    Active, not recruiting
    • Lymphoma, B-Cell
    • Nagoya, Aichi, Japan
    • +8 more
    Aug 18, 2022

    Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +11 more
    • Biopsy
    • +5 more
    • Duarte, California
      City of Hope Medical Center
    Jan 3, 2023

    Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

    Active, not recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +8 more
    • Anakinra
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2022

    Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

    Not yet recruiting
    • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
    • +21 more
    • Biopsy
    • +8 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 7, 2023

    Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory

    Approved for marketing
    • Relapsed/Refractory Diffuse Large B Cell Lymphoma
    • +3 more
    • Axicabtagene Ciloleucel
    • Duarte, California
    • +14 more
    Aug 30, 2022

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +5 more
    • La Jolla, California
    • +7 more
    Aug 25, 2023

    Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

    Not yet recruiting
    • Mature B-Cell Neoplasm
    • +25 more
    • (no location specified)
    Sep 14, 2022

    Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +13 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Aug 18, 2022

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022

    Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • CD19-targeted chimeric antigen receptor T-cell
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma Trial (Pembrolizumab, Lenalidomide 20 mg, Lenalidomide 25 mg)

    Completed
    Has Results
    • Myelodysplastic Syndrome
    • +6 more
    • Pembrolizumab
    • +2 more
    • (no location specified)
    Aug 2, 2021

    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

    Completed
    • Multiple Myeloma
    • +7 more
    • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Nov 2, 2022